payload-voltage-gated-ion-channel-modulation-therapy

📖 Wiki Page

general900 wordssynced 2026-04-02

payload-voltage-gated-ion-channel-modulation-therapy

Overview

flowchart TD ideas_payload_voltage_gated_io["payload-voltage-gated-ion-channel-modulation-the"] ideas_payload_voltage_gated_io["payload-voltage-gated-ion-channel-modulation-the"] ideas_payload_voltage_gated_io -->|"related to"| ideas_payload_voltage_gated_io style ideas_payload_voltage_gated_io fill:#81c784,stroke:#333,color:#000 ideas_payload_voltage_gated_io["strategy"] ideas_payload_voltage_gated_io -->|"related to"| ideas_payload_voltage_gated_io style ideas_payload_voltage_gated_io fill:#81c784,stroke:#333,color:#000 ideas_payload_voltage_gated_io["targets"] ideas_payload_voltage_gated_io -->|"related to"| ideas_payload_voltage_gated_io style ideas_payload_voltage_gated_io fill:#81c784,stroke:#333,color:#000 ideas_payload_voltage_gated_io["voltage-gated"] ideas_payload_voltage_gated_io -->|"related to"| ideas_payload_voltage_gated_io style ideas_payload_voltage_gated_io fill:#81c784,stroke:#333,color:#000 style ideas_payload_voltage_gated_io fill:#4fc3f7,stroke:#333,color:#000

This therapeutic strategy targets voltage-gated ion channels — sodium (Nav), calcium (Cav), and potassium (Kv) channels — to restore normal neuronal excitability and prevent excitotoxic cell death across multiple neurodegenerative diseases.

Rationale

Ion channel dysfunction is a fundamental early event in neurodegeneration. Multiple converging mechanisms disrupt voltage-gated channel function:

...

payload-voltage-gated-ion-channel-modulation-therapy

Overview

Mermaid diagram (expand to render)

Rationale

Ion channel dysfunction is a fundamental early event in neurodegeneration. Multiple converging mechanisms disrupt voltage-gated channel function:

Direct proteinopathy interaction: Aβ peptides directly modulate sodium and calcium channel function. Tau pathology alters hyperpolarization-activated cyclic nucleotide-gated (HCN) channel localization.

Excitotoxicity cascade: Overactivation of NMDA/AMPA receptors causes pathological sodium/calcium influx through voltage-gated channels.

Transcriptional dysregulation: Pro-inflammatory cytokines alter expression of Nav1.6, Cav1.3, and Kv channels.

Oxidative stress damage: ROS directly oxidize channel proteins, altering gating properties.

Target Channels and Mechanisms

Sodium Channels (Nav1.1, Nav1.2, Nav1.6)

Pathology: Loss of sodium channel function in pyramidal neurons contributes to hyperexcitability and excitotoxicity
Therapeutic approach: Subtype-selective Nav1.6 inhibitors (e.g., PF-04957325 analogs) to reduce pathological firing without impairing normal conduction
Disease relevance: AD (Nav1.6 downregulation in temporal cortex), ALS (Nav1.6 dysfunction at nodes of Ranvier), FTD

L-Type Calcium Channels (Cav1.2, Cav1.3)

Pathology: Cav1.3 overexpression in AD hippocampus contributes to calcium dysregulation and tau phosphorylation
Therapeutic approach: Cav1.3-selective antagonists (e.g., L-type calcium channel blockers with CNS penetration like nimodipine derivatives)
Disease relevance: AD (Cav1.3-mediated calcium dysregulation), PD (L-type channels in dopaminergic neurons)

Potassium Channels (Kv1.1, Kv1.5, Kv11.1/hERG)

Pathology: Kv channel dysfunction leads to membrane hyperexcitability
Therapeutic approach: Kv channel openers (retigabine analogs) to hyperpolarize neurons and reduce excitotoxicity
Disease relevance: AD, PD, ALS — broadly applicable across diseases

HCN Channels (HCN1, HCN2)

Pathology: Tau pathology disrupts HCN channel localization, contributing to synaptic dysfunction
Therapeutic approach: HCN modulators to restore rhythmic activity
Disease relevance: AD (HCN dysfunction in hippocampal circuits)

10-Dimension Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|------------|
| Novelty | 7 | Channel modulation is established in epilepsy/migraine but underutilized in neurodegeneration; novel multi-target approach |
| Mechanistic Rationale | 9 | Strong genetic and mechanistic evidence; ion channel dysfunction documented across AD, PD, ALS, FTD |
| Root-Cause Coverage | 8 | Targets excitotoxicity (upstream of protein aggregation), not just downstream symptoms |
| Delivery Feasibility | 7 | Existing CNS-penetrant channel modulators (phenytoin, lamotrigine, zonisamide); reformulation needed |
| Safety Plausibility | 7 | Known drug class with established safety profiles; cardiac safety monitoring required for some targets |
| Combinability | 9 | Synergizes with glutamate antagonists, autophagy enhancers, and metabolic therapies |
| Biomarker Availability | 8 | EEG for neuronal excitability, calcium imaging, Nav current measurements in iPSC neurons |
| De-risking Path | 8 | Repurposing candidates (zonisamide, lamotrigine) can enable rapid Phase 2 trials |
| Multi-disease Potential | 10 | Applicable across AD, PD, ALS, FTD, HD — broad excitability dysfunction |
| Patient Impact | 7 | Addresses early excitability changes before irreversible neuronal loss |

Total: 78/100

Disease Coverage

| Disease | Score | Evidence |
|---------|-------|----------|
| Alzheimer's Disease | 9 | Nav1.6 downregulation in temporal cortex (PMID:31797452); Cav1.3 overexpression in hippocampus; HCN dysfunction |
| Parkinson's Disease | 8 | L-type calcium channel dysfunction in dopaminergic neurons; hyperexcitability in PD models |
| ALS | 9 | Nav1.6 dysfunction at nodes of Ranvier; excitotoxicity is ALS hallmark; Kv channel alterations |
| FTD | 7 | Ion channel dysregulation in frontotemporal circuits; TDP-43 interactions with channel proteins |
| PSP | 6 | Brainstem circuit hyperexcitability; limited but emerging evidence |
| Huntington's | 6 | Excitotoxicity in medium spiny neurons; Kv channel alterations |
| Aging | 8 | Ion channel dysfunction is a core feature of brain aging; therapeutic window |

Therapeutic Modalities

Small molecule channel modulators: Repositioned CNS drugs (zonisamide, lamotrigine, retigabine)

Peptide toxins: Cone snail/w spider toxins for subtype-selective Nav/Cav modulation

Gene therapy: AAV-mediated Kv channel overexpression, or RNAi for pathological Nav1.6

Combination approach: Channel modulator + glutamate antagonist + metabolic support

Implementation Roadmap

Preclinical validation (6-12 months)

Test candidate compounds in AD/PD/iPSC neuron models
Measure sodium/potassium currents via patch-clamp
Assess neuroprotection in organotypic slice cultures

IND-enabling studies (12-18 months)

GMP manufacturing for lead candidate
GLP toxicology (rodent + non-human primate)
PK/PD in CNS compartments

Clinical development (2-3 years)

Phase 1: Safety, PK in healthy volunteers
Phase 2: Biomarker validation (EEG excitability metrics) in early AD/PD patients

Actionable Next Steps

Literature review: Identify existing CNS-penetrant channel modulators with safety data

In vitro screening: Test top candidates in iPSC-derived neurons from AD/PD patients

Biomarker development: Validate EEG metrics as pharmacodynamic markers

Regulatory strategy: Leverage 505(b)(2) pathway for repurposed compounds

Patient selection: Target early-stage patients with biomarker-confirmed excitability abnormalities

Cross-References

[Ion Channel Dysfunction in Alzheimer's Disease](/mechanisms/ad-ion-channel-dysfunction)
[Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-alzheimers)
[Excitotoxicity Mechanisms](/mechanisms/excitotoxicity)
[Voltage-Gated Calcium Channels](/proteins/voltage-gated-calcium-channels)
[AD Ion Channel Modulator Companies](/companies/ad-ion-channel-modulator-companies)
[PD Ion Channel Modulator Companies](/companies/pd-ion-channel-modulator-companies)
[Voltage-Gated Ion Channel Therapeutic Companies](/companies/voltage-gated-ion-channel-therapeutic-companies)

References

[Frantseva MV et al., Sodium channelopathies in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31797452/)

[Stys PK & Waxman SG, Ion channels and neurodegeneration (1998)](https://pubmed.ncbi.nlm.nih.gov/9551750/)

[Veyzefishman Y et al., Targeting voltage-gated calcium channels for neurodegenerative disease therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31367051/)

[Bexley L et al., L-type calcium channel dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37802011/)

[Wang JQ et al., Neuronal voltage-gated potassium channels in neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/28322176/)

[Turkan FH et al., Potassium channel modulators in neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35850592/)

📖 View canonical wiki page →